Quiz Answers: Treatments for presbyopia coming soon

Publication
Article
Optometry Times JournalNovember digital edition 2020
Volume 12
Issue 11

This quiz accompanies THIS article from our November issue

Click HERE to return to the quiz

1. What is the prevalence of presbyopia in the U.S.?

a. 5,000,000

b. 10,500,000

c. 50,000,000

d. 110,000,000

2. Miotics have few side effects.

a. True

b. False

3. Which of these devices uses pinhole optics (PHO)?

a. Revision Raindrop

b. Karama Inlay

c. FOV Tears

d. Allergan Presbysol

e. B and D

4. Which of these is not a pharmaco-refractive product?

a. Oraisis CSF-1

b. Presbyopia Therapies PRX-100

c. Allergan AGN

d. Eyenovia Micro-dose

e. All are pharmaco-refractive

5. What is the most common ingredient in current pharmaceutical drops for presbyopia being tested?

a. Dexamethasone

b. Pilocarpine

c. Bromfenac

d. Tropicamide

e. None of the above

6. Which of these is a device?

a. Oraisis CSF-1

b. Presbyopia Therapies PRX-100

c. Allergan AGN

d. Eyenovia Micro-dose

e. FOV Tears

7. Which is an active ingredient in PRX-100?

a. Pilocarpine

b. Tropicamide

c. Oxymetazoline

d. Polyethylene glycol

e. Diclofenac

This quiz accompanies THIS article from our November issue

Recent Videos
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Billy R. Hammond details the study, which explored how HEV-light filtering, specifically in the 380-440 nanometer range, impacts visual comfort for patients with presbyopia.
Kurt Moody, OD, FAAO, describes how to fit multifocal contact lenses in a way that patients love
Tracy Lynn Schroeder Swartz O.D., M.S., FAAO, overviews her talk on comanagement
Nick Bruns, OD, FAAO, talks premium IOLs and EVO ICL at AOA 2024.
Neda Shamie, MD, details the upcoming CIME 2024 meeting
Jacob R. Lang, OD, FAAO
The ins and outs of fitting multifocal contact lenses with Dr Jessica Crooker
© 2024 MJH Life Sciences

All rights reserved.